Browse LGMN

Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Lysosome
Domain PF01650 Peptidase C13 family
Function

Has a strict specificity for hydrolysis of asparaginyl bonds. Can also cleave aspartyl bonds slowly, especially under acidic conditions. Required for normal lysosomal protein degradation in renal proximal tubules. Required for normal degradation of internalized EGFR. Plays a role in the regulation of cell proliferation via its role in EGFR degradation (By similarity). May be involved in the processing of proteins for MHC class II antigen presentation in the lysosomal/endosomal system.

> Gene Ontology
 
Biological Process GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0003014 renal system process
GO:0006624 vacuolar protein processing
GO:0006766 vitamin metabolic process
GO:0006775 fat-soluble vitamin metabolic process
GO:0008202 steroid metabolic process
GO:0009268 response to pH
GO:0010447 response to acidic pH
GO:0016485 protein processing
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0031349 positive regulation of defense response
GO:0032801 receptor catabolic process
GO:0035264 multicellular organism growth
GO:0038127 ERBB signaling pathway
GO:0040014 regulation of multicellular organism growth
GO:0040015 negative regulation of multicellular organism growth
GO:0042359 vitamin D metabolic process
GO:0043112 receptor metabolic process
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045926 negative regulation of growth
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048638 regulation of developmental growth
GO:0048640 negative regulation of developmental growth
GO:0051402 neuron apoptotic process
GO:0051604 protein maturation
GO:0070997 neuron death
GO:1901184 regulation of ERBB signaling pathway
GO:1901185 negative regulation of ERBB signaling pathway
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901615 organic hydroxy compound metabolic process
Molecular Function GO:0004175 endopeptidase activity
GO:0004197 cysteine-type endopeptidase activity
GO:0008234 cysteine-type peptidase activity
Cellular Component GO:0005770 late endosome
GO:0005775 vacuolar lumen
GO:0043202 lysosomal lumen
GO:0045177 apical part of cell
> KEGG and Reactome Pathway
 
KEGG hsa04142 Lysosome
hsa04612 Antigen processing and presentation
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-2132295: MHC class II antigen presentation
R-HSA-1430728: Metabolism
R-HSA-6806667: Metabolism of fat-soluble vitamins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-209943: Steroid hormones
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-1679131: Trafficking and processing of endosomal TLR
R-HSA-196791: Vitamin D (calciferol) metabolism
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LGMN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LGMN and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18363997Melanoma; Colon Carcinoma; Breast Carcinoma; Lung carcinomaPromote immunity (T cell function); essential for immunotherapyFour novel oral DNA vaccines provide protection against melanoma, colon, breast, and lung carcinoma in mouse models. Vaccines are delivered by attenuated Salmonella typhimurium to secondary lymphoid organs and respectively target vascular endothelial growth factor receptor-2, transcription factor Fos-related antigen-1, anti-apoptosis protein survivin and Legumain, an asparaginyl endopeptidase specifically overexpressed on tumor-associated macrophages (TAMs) in the tumor microenvironment (TME). Key mechanisms induced by these DNA vaccines include efficient suppression of angiogenesis in the tumor vasculature and marked activation of cytotoxic T cells, natural killer cells, and antigen-presenting dendritic cells.
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LGMN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LGMN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2560.366
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1510.962
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3240.882
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3680.376
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2380.906
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1340.656
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0280.958
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2560.905
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3170.9
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4040.503
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7120.617
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0140.891
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LGMN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LGMN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LGMN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LGMN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LGMN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LGMN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LGMN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLGMN
Namelegumain
Aliases LGMN1; PRSC1; protease, cysteine, 1 (legumain); AEP1; asparaginyl endopeptidase; cysteine protease 1; protea ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LGMN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.